Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.50 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26017810 | 0.99 | CRBN (0.61) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20129036 | 0.98 | CRBN (0.58) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20129044 | 0.97 | CRBN (0.59) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20128898 | 0.94 | CRBN (0.58) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL27098059 | 0.93 | CRBN (0.59) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22906659 | 0.93 | CRBN (0.59) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL26270620 | 0.92 | CRBN (0.64) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25207204 | 0.90 | CRBN (0.59) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25211098 | 0.90 | CRBN (0.62) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29426741 | 0.90 | CRBN (0.59) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | GENENTECHT, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885DDB1 750/4885ALDH1A1 798/4885 |
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, TEAD2, TEAD4 | CRBN 2808/4885DDB1 750/4885ALDH1A1 1089/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | CRBN 3/4885DDB1 434/4885ALDH1A1 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.